Vaxcyte

Founded in 2013, we are a biotechnology research company focused on creating innovative vaccines. We develop high-fidelity vaccines that protect against bacterial diseases. We currently employ between 201 and 500 individuals.

Our XpressCF® system allows us to quickly produce complex proteins and antigens for high-fidelity vaccines with better immune responses. This method uses advanced synthetic chemistry to overcome the limitations of traditional, cell-based vaccine approaches. The platform is licensed exclusively from Sutro Biopharma, Inc.

Our pipeline includes several vaccine candidates. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV), is in Phase 3 adult and Phase 2 infant clinical trials for preventing invasive pneumococcal disease (IPD). VAX-24, a 24-valent PCV candidate, covers more serotypes than existing infant PCVs. Both VAX-31 and VAX-24 aim to improve current PCVs. They target serotypes that frequently cause IPD, are linked to high death rates, antibiotic resistance, and meningitis, while also covering previously circulating strains. VAX-XL is in earlier development, using our carrier-sparing, site-specific conjugation technology to broaden our PCV coverage. We also have VAX-A1, a vaccine candidate for Group A Strep infections, and VAX-GI, which targets Shigella. We recently announced that the first participants have been dosed in a Phase 3 study for VAX-31 and expect to start another Phase 3 study in adults in the first quarter of 2026.

Our mission is to eliminate bacterial infections, such as invasive pneumococcal disease, Group A Strep, and Shigella, protecting people worldwide. We are driven by the urgent need to prevent or treat these infections, especially given rising antimicrobial resistance.

We believe there’s a significant opportunity to transform vaccine manufacturing using our advanced chemistry platform, moving past traditional development methods. Our primary focus is to develop high-fidelity vaccines that protect people from bacterial diseases globally. We aim to develop broader-spectrum pneumococcal conjugate vaccines (PCVs) using our site-specific, carrier-sparing platform. We are also exploring prevention for pathogens like Group A Strep and Shigella, for which no vaccines currently exist.

We cultivate a creative and collaborative culture that offers meaningful career opportunities. We are dedicated to reducing the incidence of invasive pneumococcal disease and other bacterial infections.

We set ambitious goals and foster a learning culture that challenges our employees. Our leadership aims to create a supportive environment. We invest in professional growth through coaching and development, and we recognize that our employees have lives beyond work. Employees highlight our growth potential, opportunities to shape the company, and the chance to positively impact global health. Our work environment is agile, with an empowering leadership team.

We provide our employees with a comprehensive range of benefits, including:

• 100% paid health, dental, and vision insurance
• A 401k matching program
• Flexible paid time off and holidays
• Paid parental leave
• Paid sick leave
• Equity awards (stock options & RSUs)
• Employee Stock Purchase Plan
• Hybrid work schedule
• Health Savings Account (HSA)
• Flexible Spending Account (FSA)
• Lifestyle Spending Account
• Basic Life/AD&D Insurance
• Short and Long-Term Disability Insurance
• Health Activity and Commuter Programs
• Employee Assistance Program
• Coaching for new and existing parents
• Mental health and wellness resources
• Employee Career Development Program